ReviewMolecules (Basel, Switzerland)2023
A Review on Recent Approaches on Molecular Docking Studies of Novel Compounds Targeting Acetylcholinesterase in Alzheimer Disease.
Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Rational drug design and synthesis of novel bioactive molecules with oxygen heterocycles, including AChE and BChE inhibitory properties and SAR studies.Molecular diversity · 2026Review
- An Integrated in Silico, in Vitro, and in Vivo Assessment of the Antioxidant and Neuroprotective Profile of Selenocyanate Compounds.Biological trace element research · 2026Article
- Computational identification of novel acetylcholinesterase inhibitors as potential treatments for Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2026Article
- Unlocking the Potential of Isatin Scaffolds in Acetylcholinesterase Inhibition.Archiv der Pharmazie · 2026Review
- Design, synthesis and pharmacological evaluation of coumarin tethered 1,3,4-oxadiazole conjugates as dual binding site acetylcholinesterase ligands targeting Alzheimer's disease.Molecular diversity · 2026Article
- 2-(Arylamino)thiazol-4(5H)-ones Mitigate Oxidative Stress and Confer Neuroprotection in Cellular andInternational journal of molecular sciences · 2026Article
- Recent Advances in Pyrazole-Based Cholinesterase Inhibitors: Medicinal Chemistry Perspectives from 2020 to 2025.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Essential Oil ofMolecules (Basel, Switzerland) · 2026Article
- Structure-Guided Optimization of 1,2,4-Triazole-Thione-Based Mannich Derivatives as Dual-Target Modulators: AChE/MAO-B.Chemical biology & drug design · 2026Article
- Integrating In Vitro Bioactivities and In Silico Molecular Evaluation ofMolecules (Basel, Switzerland) · 2026Article
- BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.International journal of molecular sciences · 2026Article
- Molecular Mechanistic Studies on Caffeoylquinic Acid Derivatives From Vaccinium dunalianum Wight as Dual-Target Inhibitors of AChE and BChE With In Vitro Inhibitory Evaluation and Molecular Docking.Chemistry & biodiversity · 2026Article
- Antioxidant, Anti-Cholinesterase, and Neuroprotective Properties ofAntioxidants (Basel, Switzerland) · 2026Article
- Mapping the Polar Neuro-Interactome ofLife (Basel, Switzerland) · 2026Article
- New benzimidazole-alkanesulfonate conjugates as cholinesterase inhibitors with in vitro and in silico validation.Scientific reports · 2026Article
- Article
- Design, synthesis and evaluation of new pyrazino[1',2':1,5]pyrrolo[2,3-RSC advances · 2026Article
- Enzymatic Biomarkers for Early Diagnosis of Alzheimer's Disease: Uncovering Key Targets and Mechanisms.CNS & neurological disorders drug targets · 2026Review
- Computer-aided Drug Design for Alzheimer's Disease: Recent Advancements and Future Perspectives.Current topics in medicinal chemistry · 2026Review
- Six-membered N-heterocyclic alkaloids as ChE inhibitors in alzheimer's disease treatment.Metabolic brain disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), a neurodegenerative brain disorder that affects millions of people worldwide, is characterized by memory loss and cognitive decline. Low levels of acetylcholine and abnormal levels of beta-amyloid, T protein aggregation, inflammation, and oxidative stress, have been associated with AD, and therefore, research has been oriented towards the cholinergic system and primarily on acetylcholinesterase (AChE) inhibitors. In this review, we are focusing on the discovery of AChE inhibitors using computer-based modeling and simulation techniques, covering the recent literature from 2018-2022. More specifically, the review discusses the structures of novel, potent acetylcholinesterase inhibitors and their binding mode to AChE, as well as the physicochemical requirements for the design of potential AChE inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.